Triple Therapy with Ecabet Sodium, Amoxicillin and Lansoprazole for 2 Weeks as the Rescue Regimen for H. pylori Infection

• Furuta Takahisa

  Center for Clinical Research, Hamamatsu University School of Medicine, Japan

• Kato Mototsugu

  Division of Endoscopy, Hokkaido University Hospital, Japan

• Sugimoto Mitsushige

  Center for Clinical Research, Hamamatsu University School of Medicine, Japan

• Sasaki Makoto

  Department of Gastroenterology, Aichi Medical University School of Medicine, Japan

• Kamoshida Toshiro

  Department of Internal Medicine, Hitachi General Hospital, Japan

• Furukawa Kouichi

  Department of Gastroenterology, Niigata City General Hospital, Japan

• Inaba Tomoki

  Department of Gastroenterology, Kagawa Prefectural Central Hospital, Japan

• Tomita Takashige

  Department of Gastroenterology, Toshiba General Hospital, Japan

• Shirai Takayuki

  Department of Internal Medicine, Tokai University School of Medicine, Japan

• Ishii Naoki

  Department of Gastroenterology (Gastroenterology Center), St. Luke's International Hospital, Japan

• Nomura Hideyuki

  The Center for Liver Disease, Shin-Kokura Hospital, Japan

• Konda Yoshitaka

  Department of Gastroenterology, Higashiyama Takeda Hospital, Japan

• Asaka Masahiro

  Department of Gastroenterology, Hokkaido University Graduate School of Medicine, Japan

• the JAPAN GAST STUDY GROUP

Abstract

Background/Aim Ecabet sodium has an anti-H. pylori effect. We assessed the efficacy of ecabet sodium in the rescue therapy for the eradication of H. pylori.<br> Methods A total of 74 patients with failed eradication of H. pylori after triple therapy with lansoprazole 30 mg bid, amoxicillin 750 mg bid and clarithromycin 200 mg bid were enrolled. They were randomly assigned to the three treatment groups as follows: LAC, lansoprazole 30 mg + amoxicillin 750 mg + clarithromycin 200 mg bid for 1 week; LAC2E, lansoprazole 30 mg bid + amoxicillin 750 mg bid + clarithromycin 200 mg bid + ecabet sodium 2 g bid for 1 week; and LA2E, lansoprazole 30 mg bid + amoxicillin 750 mg bid + ecabet sodium 2 g bid for 2 weeks. Eradication of H. pylori was assessed by the 13C-urea breath test after treatment.<br> Results Eradication rates in intention-to-treat and per-protocol analyses were 20.0% (95% CI: 6.8-40.7) and 20.0% (6.8-40.7) with LAC, respectively, and 16.0% (4.5-36.1) and 17.4% (5.0-38.8) with LAC2E. In contrast, respective rates with LA2E were 75% (53.3-90.2) and 85.7% (63.7-97.0), which were significantly higher than those with LAC (p<0.001 for both ITT and PP) and LAC2E (p<0.001 for both ITT and PP).<br> Conclusion Triple therapy with ecabet sodium, lansoprazole and amoxicillin for 2 weeks was effective as the rescue therapy after failure of the standard clarithromycin-based regimen.<br>

Journal

• Internal Medicine

  Internal Medicine 50 (5), 369-374, 2011

  The Japanese Society of Internal Medicine

Keywords

• Ecabet sodium
• <i>H. pylori</i>
• eradication
• resistance
• clarithromycin
• metronidazole

Details

• CRID: 1390282679849550080
• NII Article ID: 130000649845
• DOI: 10.2169/internalmedicine.50.4305
• ISSN: 13497235
• ISSN: 09182918
• Web Site: http://www.jstage.jst.go.jp/article/internalmedicine/50/5/50_5_369/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2012013274
• Text Lang: en
• Data Source:
  • JaLC
  • Crossref
  • CiNii Articles
  • KAKEN
• Abstract License Flag: Disallowed